Eli Lilly reported that its combination treatment eloraTZP, combining an amylin receptor agonist with Zepbound, achieved 23.3% average weight loss in patients with obesity/overweight and type 2 diabetes, outperforming its triple-G candidate retatrutide in this population. At the highest dose, patients lost an average of 54.1 pounds over 48 weeks with improved blood sugar control, though gastrointestinal adverse events led to discontinuation in up to 27% of patients. Lilly plans to initiate phase 3 trials in late 2026.
Eli Lilly presented detailed phase 3 data for retatrutide, a triple-G obesity drug, showing 34.9% of patients on the highest dose lost at least 25% of body weight compared to 4% on placebo. The company plans to file for FDA approval in Q1 2025, positioning retatrutide to compete with its existing tirzepatide while demonstrating superior weight loss but more modest blood sugar effects.